跳至主要内容
临床试验/NCT03319823
NCT03319823撤回4 期

A Pilot Study: Treating Nocturnal Hypertension and Nocturia in African American Men

Cedars-Sinai Medical Center1 个研究点 分布在 1 个国家开始时间: 2017年10月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
试验地点
1
主要终点
change nocturnal systolic blood pressure in relation with frequency of nocturia

研究概览

简要总结

This is a protocol to obtain pilot data to submit a new NIH grant on Nocturnal Hypertension and Nocturia. In the diversity supplement to Dr. Victor's current NIH grant (Cut Your Pressure Too: The Los Angeles Barbershop Blood Pressure Study) the results show that uncontrolled systolic hypertension is an independent determinant of nocturia in African American men.

the investigators now want to pursue this correlation by designing a new NIH grant proposal to determine whether replacing short acting with long acting drugs and dosing them at bedtime rather than in the morning will: A. Lower systolic blood pressure during sleep B. Improve nocturia and result in better sleep quality

详细描述

Aims and Significance of pilot data

Determine:

  1. The feasibility of the Southern California Healthy Heart and Blood Pressure registry as an effective method to recruit African American men to participate in a new research program
  2. If participants are willing to comply with the study procedures including wearing an activity monitor, sleep study device, and ambulatory blood pressure monitor
  3. The within subject variation for repeated measures of nocturnal blood pressure by ambulatory blood pressure and activity monitoring
  4. If nocturnal systolic blood pressure is higher in men with self-reported nocturia ≥2 than in men with 0-1 nocturia
  5. If use of long-acting antihypertensive medication as well as nighttime dosing of medication can lower nocturnal systolic blood pressure and reduce nocturia

Purpose:

Obtain key pilot data to show feasibility and document the reproducibility of the proposed measurements.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
35 Years 至 59 Years(Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •African American Men
  • •Age 35 to 59 years-old
  • •Able to give informed consent
  • •Willing to wear the activity monitor, ambulatory blood pressure monitoring (ABPM), and sleep study device
  • •Uncontrolled hypertension: both a sleeping average systolic blood pressure of ≥ 125 mm Hg and an awake average systolic blood pressure of ≥ 135 mm Hg

排除标准

  • •Severe Sleep Apnea (Apnea Hypopnea Index (AHI) of > 30 on home sleep study) or history of sleep apnea diagnosis and use of Continuous Positive Airway Pressure therapy
  • •Uncontrolled Diabetes Mellitus (a random glucose of ≥ 200 mg/dL)
  • •History of diagnosis or symptoms of either prostate disease or overactive bladder (urinary urgency or frequency during the daytime)
  • •Chronic kidney disease (Glomerular filtration rate of < 60 mL/min/1.73 m2 based on the MDRD equation)
  • •Renal transplant recipient
  • •Loop diuretic use
  • •Night shift work
  • •On chemotherapy for cancer
  • •Orthostatic hypotension
  • •o After 2 minutes of standing: a drop in blood pressure of > 20/10 mm Hg, a standing systolic blood pressure of < 100 mm Hg, or tachycardia with an increased heart rate of > 20 beats/minute
  • •Other reasons deemed unsafe for study participation by Principle Investigator

研究组 & 干预措施

Thiazide Therapy Group

Experimental

• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of < 160 mm Hg

干预措施: Thiazide Treatment Group (Drug)

Thiazide Therapy Group

Experimental

• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of < 160 mm Hg

干预措施: Intensified Thiazide Treatment Group (Drug)

Combination Therapy Group

Experimental

• Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg.

干预措施: Combination Medication Treatment Group (Drug)

结局指标

主要结局

change nocturnal systolic blood pressure in relation with frequency of nocturia

时间窗: change from baseline at 12 weeks after treatment initiation.

measurement of nocturnal systolic blood pressure will occur with continuous ambulatory blood pressure monitors. nocturia frequency will be self reported by participant and then verified by activity monitor (actigraph) built in the ambulatory blood pressure monitor .

Night time blood pressure medication dosing in relation with frequency of Nocturia

时间窗: Change of systolic blood pressure from baseline at 12 weeks.

the use of long-acting antihypertensive medication as well as nighttime dosing of medication can lower nocturnal systolic blood pressure and reduce the frequency of nocturia which will be self reported by participant and then verified by activity monitor (actigraph) built in the ambulatory blood pressure monitor .

change in the systolic blood pressure in participants

时间窗: Change from Baseline Systolic Blood Pressure at 12 weeks

The within subject variation in millimeter of mercury for repeated measures of nocturnal systolic blood pressure by ambulatory blood pressure.

Participant Compliance

时间窗: 12 weeks

If participants are willing to comply with the study procedures including wearing an activity monitor (it is built in the ambulatory blood pressure monitor), sleep study device, and ambulatory blood pressure monitor

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Florian Rader

Co-Director, Clinic for Hypertrophic Cardiomyopathy and Aortopathies

Cedars-Sinai Medical Center

研究点 (1)

Loading locations...

相似试验

Treating Nocturnal Hypertension and Nocturia in... | 临床试验